{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:12:44Z","timestamp":1768788764433,"version":"3.49.0"},"reference-count":19,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","award":["Junior Clinician Scientist Stipend"],"award-info":[{"award-number":["Junior Clinician Scientist Stipend"]}],"id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,2,17]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8\u201317.0) months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-002262","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T12:23:07Z","timestamp":1617193387000},"page":"e002262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-7997","authenticated-orcid":false,"given":"Justin","family":"Ferdinandus","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Kessler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West German Cancer Center, Ruhrlandklinik, University Hospital Essen, University Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Otto","family":"Kambartel","sequence":"additional","affiliation":[{"name":"Bethanien Hospital Moers, Lung Center, Moers, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried Ernst Erich","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang Peter","family":"Fendler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Faehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, Hospital Esslingen, Esslingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Christian","family":"Christoph","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Haematology, Evang. Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2025100308102574000_9.3.e002262.1","doi-asserted-by":"crossref","first-page":"S1181","DOI":"10.1016\/j.annonc.2020.08.2284","article-title":"LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \u226550%","volume":"31","author":"Brahmer","year":"2020","journal-title":"Annals of Oncology"},{"key":"2025100308102574000_9.3.e002262.2","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.jtho.2019.08.486","article-title":"OA14.04 five-year outcomes from the randomized, phase 3 trials CheckMate 017\/057: nivolumab vs docetaxel in previously treated NSCLC","volume":"14","author":"Gettinger","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"2025100308102574000_9.3.e002262.3","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year Fixed-Duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100308102574000_9.3.e002262.4","first-page":"493","article-title":"Nivolumab in Nonsquamous non-small-cell lung cancer","volume":"374","author":"Borghaei","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100308102574000_9.3.e002262.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"2025100308102574000_9.3.e002262.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025100308102574000_9.3.e002262.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025100308102574000_9.3.e002262.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2025100308102574000_9.3.e002262.9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"Fdg-Pet response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100308102574000_9.3.e002262.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res"},{"key":"2025100308102574000_9.3.e002262.11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by \n                  18\n               F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100308102574000_9.3.e002262.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100308102574000_9.3.e002262.13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with Escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100308102574000_9.3.e002262.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7235"},{"key":"2025100308102574000_9.3.e002262.15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","article-title":"The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy","volume":"44","author":"Wong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100308102574000_9.3.e002262.16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1148\/radiol.2018180572","article-title":"Pembrolizumab-induced Sarcoid-like reactions during treatment of metastatic melanoma","volume":"289","author":"Cheshire","year":"2018","journal-title":"Radiology"},{"key":"2025100308102574000_9.3.e002262.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.11.010"},{"key":"2025100308102574000_9.3.e002262.18","doi-asserted-by":"crossref","first-page":"S1474","DOI":"10.21037\/jtd.2018.05.90","article-title":"Lung cancer, elderly and immune checkpoint inhibitors","volume":"10","author":"Casaluce","year":"2018","journal-title":"J Thorac Dis"},{"key":"2025100308102574000_9.3.e002262.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"}],"updated-by":[{"DOI":"10.1136\/jitc-2020-002262corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:10:35Z","timestamp":1759504235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-002262"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002262","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jitc-2020-002262corr1","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}